Windtree Therapeutics INC /DE/ S-1 registration statements

Windtree Therapeutics, Inc. has been delisted from Nasdaq, faces substantial doubt about its ability to continue as a going concern, and is pivoting to a new strategy focused on acquiring revenue-generating FDA-approved products.

Windtree Therapeutics, a biotechnology company, has filed an S-1/A registration statement to allow selling stockholders to resell up to 62.6 million shares of common stock, with the company not receiving any proceeds from these sales, while facing substantial doubt about its ability to continue as a going concern.

Windtree Therapeutics, a biotechnology company, filed an S-1/A to register the resale of up to 42.17 million common shares by selling stockholders, while pursuing a new corporate strategy focused on acquiring revenue-generating FDA-approved products and advancing its clinical pipeline, despite significant accumulated deficits and ongoing capital requirements.

Windtree Therapeutics is registering for the resale of up to 42,168,035 shares of its common stock, issuable upon conversion of Series D convertible preferred stock held by selling stockholders.

Windtree Therapeutics is registering up to 31,247,383 shares of common stock for resale by selling stockholders, including shares issuable upon conversion of preferred stock, exercise of warrants, and under an equity line of credit agreement.

Windtree Therapeutics is registering for resale up to 31.2 million shares of common stock by selling stockholders, including shares issuable upon conversion of preferred stock and notes, exercise of warrants, and under an equity line of credit.

Windtree Therapeutics is registering for the resale of up to 40 million shares of its common stock, issuable under an equity line of credit agreement, by a selling stockholder.

Windtree Therapeutics has filed a registration statement for the potential resale of up to 10,679,758 shares of common stock by Seven Knots, LLC, under an equity line of credit agreement.

Windtree Therapeutics files for an offering of common stock and warrants to fund clinical development of istaroxime and preclinical development of its aPKCi inhibitor asset platform.